Fig. 2.

Annualized mean diabetes-related health care costs at baseline and during follow-up among insulin glargine and liraglutide patients from the OptumInsight (a) and HealthCore (b) Databases. All other differences were not statistically different. Diabetes-related health care costs included costs from medical claims with a primary or secondary diagnosis of diabetes (ICD-9-CM: 250.xx), or pharmacy claims for diabetes medication including oral anti-diabetes drugs, insulin, glucagon-like peptide-1 receptor agonists, and pramlintide. N/A not applicable